PageOverview.com
 

Websites, domains, hosts that links to novartispharmaceuticals.com

Our database shows, that the website novartispharmaceuticals.com is linked by a total of 10 websites.

 
Number of websites/domains displayed: 10
Results found: 10
 

Websites discovered:

IL-17A Antagonist for PsO, PsA, & AS - COSENTYX (secukinumab)
http://pageoverview.com/website-report/cosentyxhcp.com
Learn about COSENTYX (secukinumab), the first fully human IL-17A antagonist approved for plaque psoriasis, psoriatic arthritis, andankylosing spondylitis.
  • Expected expiration: May 18th in 2019
  • Creation date: May 18th in 2015
  • Renew date: April 17th in 2017
ノバルティス
http://pageoverview.com/website-report/totalcare-copd.jp
  • Expected expiration: August 31st in 2017
  • Creation date: August 31st in 2012
  • Renew date: April 4th in 2017
Relapsing-remitting MS Treatment – Gilenya (fingolimod)
http://pageoverview.com/website-report/gilenyahcp.com
Learn more about Gilenya, a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing-remitting MS. See ISI for details.
  • Expected expiration: May 18th in 2019
  • Creation date: May 18th in 2015
  • Renew date: April 17th in 2017
МОНОС ГРУПП
http://pageoverview.com/website-report/monos.mn
  • Expected expiration: April 13th in 2018
  • Creation date: April 13th in 2005
  • Renew date: April 13th in 2017
  • Google Analytics: 75784511-1
Explore Stories | Novartis
http://pageoverview.com/website-report/novartispharmaceuticals.com
Explore stories about how Novartis innovation has impacted people worldwide.
  • Expected expiration: May 16th in 2018
  • Creation date: May 16th in 2001
  • Renew date: April 14th in 2016
Chronic Heart Failure (HFrEF) Treatment – ENTRESTO (sacubitril/valsartan) tablets
http://pageoverview.com/website-report/entrestohcp.com
Learn about ENTRESTO (sacubitril/valsartan), the HFrEF treatment for patients with chronic heart failure (NYHA Class II–IV) and reduced ejection fraction.
  • Expected expiration: May 7th in 2019
  • Creation date: May 7th in 2015
  • Renew date: April 6th in 2017
ウェブサイト一時閉鎖のお知らせ | ノバルティス
http://pageoverview.com/website-report/tahatuseikoukasyo.jp
  • Expected expiration: November 30th in 2017
  • Creation date: November 21st in 2012
  • Renew date: December 1st in 2016
Multiple Sclerosis Treatment | EXTAVIA
http://pageoverview.com/website-report/extaviahcp.com
EXTAVIA is a disease-modifying therapy (DMT) for people with relapsing forms of multiple sclerosis (MS). Learn about multiple sclerosis treatment and therapy.
  • Expected expiration: May 18th in 2019
  • Creation date: May 18th in 2015
  • Renew date: April 17th in 2017
Heart Failure | Heart Attack Information | Novartis
http://pageoverview.com/website-report/heartfailure.com
~50% of all heart failure patients die by 5 years of diagnosis¹. Healthcare professionals, find out more on www.heartfailure.com
  • Expected expiration: November 11th in 2019
  • Creation date: November 12th in 1996
  • Renew date: October 10th in 2017
Health Care Social Media – Monitoring The Pulse Of Health Care Social Media
http://pageoverview.com/website-report/hcsmmonitor.com
Personally, I feel to ignore the intersection between health care and social media is to potentially ignore our own relevance as a health care practitioner during the next decade ~ Howard Luks, MD orthopedic surgeon and digital media and medicine specialist. Beyond The Buzz Healthcare social media is more than just a marketing buzzword; as…
  • Expected expiration: June 13th in 2019
  • Creation date: June 13th in 2012
  • Renew date: January 15th in 2017
0.0127 // 2024-05-07 09:56:18
All Rights reserved 2018 © PageOverview.com